LKQ CORP
No SEC Form 4 filings for $LKQ in the last 30 days.
Capricor Therapeutics (CAPR) fell 36% to a 52-week low after an FDA advisory committee voted 9-3 against recommending Deramiocel approval, citing clinical evidence concerns. JonesResearch downgraded CAPR to Hold. LKQ dropped 14% to a six-year low after Q2 revenue and EPS missed estimates and guidance was cut. Paramount Skydance (PSKY) slid 2% on ongoing legal issues around its Warner Bros. Discovery deal.
LKQ’s Q2 2026 earnings call focused on analyst questions after a negative market reaction. CEO Justin Jude attributed Europe disruption to Germany’s new ERP rollout, citing service issues and revenue loss, while North America achieved positive organic growth for the first time in nine quarters. CFO Rick Galloway said no further ERP conversions are planned this year and noted a 40% tariff reduction on Taiwanese imports.
LKQ’s Q2 2026 call said North America posted its first positive organic growth in nine quarters. A Germany ERP conversion disrupted service levels, causing an estimated $140m revenue headwind and $50m EBITDA hit in Q2. Alternative part utilization hit a record above 40%. Full-year outlook targets recovery to 100% run rates by end-2026; free cash flow to reduce revolver after $500m prepayment.
Over the past 7 days, alphai's AI scored 2 news stories mentioning LKQ (LKQ CORP). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent LKQ coverage spans earnings and market movers.
Operational disruption from a Germany software rollout is pressuring margins and cash flow, prompting guidance reset.
Near-term focus is on whether Germany service restoration and revenue recapture progress, while U.K. competition and Specialty margin headwinds stabilize after one-time credit loss.
Germany ERP disruption and revised recovery assumptions are the core near-term earnings risk, partially offset by North America organic growth and record APU.
Guidance reset plus Europe/ERP disruption and litigation overhang increases downside risk to margins and cash generation.
Guidance reset is the key tradable catalyst, with Europe disruption and margin drag likely driving near-term sentiment and estimates.
alphai scores every news story that mentions LKQ with an AI model for sentiment and relevance, and aggregates insider trades from LKQ CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Capricor Therapeutics (CAPR) fell 36% to a 52-week low after an FDA advisory committee voted 9-3 against recommending Deramiocel approval, citing clinical evidence concerns. JonesResearch downgraded CAPR to Hold. LKQ dropped 14% to a six-year low after Q2 revenue and EPS missed estimates and guidance was cut. Paramount Skydance (PSKY) slid 2% on ongoing legal issues around its Warner Bros. Discovery deal.
4 min readLKQ’s Q2 2026 earnings call focused on analyst questions after a negative market reaction. CEO Justin Jude attributed Europe disruption to Germany’s new ERP rollout, citing service issues and revenue loss, while North America achieved positive organic growth for the first time in nine quarters. CFO Rick Galloway said no further ERP conversions are planned this year and noted a 40% tariff reduction on Taiwanese imports.
4 min readLKQ’s Q2 2026 call said North America posted its first positive organic growth in nine quarters. A Germany ERP conversion disrupted service levels, causing an estimated $140m revenue headwind and $50m EBITDA hit in Q2. Alternative part utilization hit a record above 40%. Full-year outlook targets recovery to 100% run rates by end-2026; free cash flow to reduce revolver after $500m prepayment.
7 min readLKQ (Nasdaq: LKQ) shares fell about 0.7% to $22.45 after earnings. Adjusted EPS was $0.67 for the quarter. The company cut full-year adjusted earnings guidance to $2.60 to $2.90 and trimmed free cash flow outlook. Q2 revenue was $3,408m, down ~2.6% year over year.
6 min readThursday, July 30, 2026 at 8:00 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Justin Jude Senior Vice President and Chief Financial Officer - Rick Galloway Vice President of Investor Relations - Joseph Boutross TAKEAWAYS Revenue -- $3.4 billion, a decrease from $3.5 billion in the prior year period. Adjusted Diluted EPS -- $0.67, compared to $0.84 last year, reflecting lower profitability in Europe.
6 min readANTIOCH, Tenn. (AP) — ANTIOCH, Tenn. (AP) — LKQ Corp. (LKQ) on Thursday reported second-quarter net income of $136 million. The Antioch, Tennessee-based company said it had profit of 53 cents per share. Earnings, adjusted for one-time gains and costs, were 67 cents per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for earnings of 73 cents per share.
2 min readLKQ Corporation reported Q2 2026 revenue of $3.41B, down 3% year over year. Net income fell to $136M and EPS was $0.53. The company cited operational challenges in Europe, with modest growth in North America and Specialty but lower margins. It said liquidity is strong and the board is reviewing strategic alternatives.
1 min readLKQ reported Q2 results, including organic revenue down 4.4% year over year versus a -0.9% average estimate. Organic growth was 0.5% in North America wholesale parts and services versus -0.3% expected, and 20.7% in other versus 19.2%. Revenue for Europe parts and services was $1.45B vs $1.56B estimated.
4 min readLKQ shares fell about 13.9% in pre-open after the company reported Q2 2026 results below Wall Street expectations on EPS and revenue and cut full-year adjusted EPS guidance to a midpoint of $2.75, down nearly 10%. Adjusted EPS was $0.67 vs $0.71 consensus, revenue $3.41B vs $3.49B. Margins and free cash flow margin also declined.
3 min readLKQ (NASDAQ: LKQ) reported Q2 CY2026 revenue of $3.41 billion, down 6.4% year on year, missing analysts’ estimates. Non-GAAP EPS was $0.67, about 6% below consensus. The company cited North America growth and Specialty performance, while Europe was affected by a Germany ERP rollout. Shares fell 13.9% to $22.73.
4 min read
